甲磺酸伏美替尼片致心力衰竭1例分析

doi:10.19803/j.1672-8629.20240433

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (1): 113-115.
DOI: 10.19803/j.1672-8629.20240433

甲磺酸伏美替尼片致心力衰竭1例分析

张维¹, 徐东杰², 金宇³, 邹颖⁴, 张婷⁴, 周建成^4,*

¹南京中医药大学附属南京医院,南京市第二医院药学部,江苏南京 210003;
²南京医科大学第一附属医院心内科,江苏南京 210029;
³南京医科大学第一附属医院呼吸与危重症医学科,江苏南京 210029;
⁴南京医科大学第一附属医院药学部,江苏南京 210029

收稿日期:2024-06-26 出版日期:2025-01-15 发布日期:2025-01-22
通讯作者: ^*周建成,男,本科,主管药师,临床药学。E-mail: zhoujiancheng1646@126.com
作者简介:张维,女,本科,药师,临床药学。

One Case of Heart Failure Caused by Furmonertinib Mesilate Tablets

ZHANG Wei¹, XU Dongjie², JIN Yu³, ZOU Ying⁴, ZHANG Ting⁴, ZHOU Jiancheng^4,*

¹Department of Pharmacy, the Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing Jiangsu 210003, China;
²Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing Jiangsu 210029, China;
³Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing Jiangsu 210029, China;
⁴Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing Jiangsu 210029, China

Received:2024-06-26 Online:2025-01-15 Published:2025-01-22

摘要/Abstract

摘要： 目的探讨甲磺酸伏美替尼片（简称“伏美替尼”）引起心力衰竭的临床表现、发生机制及治疗策略。方法分析1例肺癌晚期的女性患者接受第三代表皮生长因子受体-酪氨酸激酶抑制剂（伏美替尼）后出现心力衰竭,结合文献讨论其潜在发病机制和治疗措施。结果患者服用伏美替尼3个月后出现心力衰竭,排除其他因素后,结合同类药物致心力衰竭报告,考虑伏美替尼引起心力衰竭可能。患者经伏美替尼减量和抗心衰治疗后好转。结论伏美替尼治疗可引起心力衰竭,临床应用时注意监测心脏彩超,以尽早识别和处置。

关键词: 甲磺酸伏美替尼, 表皮生长因子受体-酪氨酸激酶抑制剂, 肺恶性肿瘤, 心力衰竭, QT间期延长, 药品不良反应

Abstract: Objective To investigate the clinical characteristics, mechanism and treatment strategies of heart failure caused by furmonertinib mesilate tablets. Methods A case of heart failure caused by the third generation of epidermal growth factor receptor-tyrosine kinase inhibitor (furmonertinib) in a female patient with advanced lung cancer was summarized. The potential mechanism and treatment strategies were studied based on a literature review. Results The patient developed heart failure 3 months after administration of furmonertinib. Considering that similar medication had been reported to induce heart failure, furmonertinib was believed to have induced heart failure in this patient after other potential risks were ruled out. Her cardiac function improved after reduction of the dosage of furmonertinib and anti-heart failure therapy. Conclusion The use of furmonertinib can cause heart failure, so echocardiography should be monitored for early identification and management in clinical practice.

Key words: Furmonertinib Mesilate, Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Lung Cancer, Heart Failure, QT Interval Prolongation, Adverse Drug Reaction

中图分类号:

张维, 徐东杰, 金宇, 邹颖, 张婷, 周建成. 甲磺酸伏美替尼片致心力衰竭1例分析[J]. 中国药物警戒, 2025, 22(1): 113-115.

ZHANG Wei, XU Dongjie, JIN Yu, ZOU Ying, ZHANG Ting, ZHOU Jiancheng. One Case of Heart Failure Caused by Furmonertinib Mesilate Tablets[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 113-115.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240433

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I1/113

参考文献

[1] CHEN L, ZHOU Y, GAN C, et al.Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences[J]. Cancer Invest, 2022, 40(7): 590-603.
[2] SHI Y, HU X, ZHANG S, et al.Efficacy, Safety, and Genetic Analysis of Furmonertinib (AST2818) in Patients with EGFR T790M Mutated Non-Small-Cell Lung Cancer: a Phase 2b, Multicentre, Single-Arm, Open-Label Study[J]. Lancet Respir Med, 2021, 9(8): 829-839.
[3] SHI Y, CHEN G, WANG X, et al.Furmonertinib (AST2818) vs Gefitinib as First-Line Therapy for Chinese Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer (FURLONG): a Multicentre, Double-Blind, Randomised Phase 3 Study[J]. Lancet Respir Med, 2022, 10(11): 1019-1028.
[4] AN T, HAN S.Cardiovascular Toxicity of Targeted Therapy in Patients with Lung Cancer[J]. Chin J Clin Oncol(中国肿瘤临床), 2021, 48(6): 311-316.
[5] ANAND K, ENSOR J, TRACHTENBERG B, et al.Osimertinib-Induced Cardiotoxicity: a Retrospective Review of the FDA Adverse Events Reporting System (FAERS)[J]. JACC CardioOncol, 2019, 1(2): 172-178.
[6] KUNIMASA K, KAMADA R, OKA T, et al.Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated with Osimertinib[J]. JACC CardioOncol, 2020, 2(1): 1-10.
[7] EWER MS, TEKUMALLA SH, WALDING A, et al.Cardiac Safety of Osimertinib: a Review of Data[J]. J Clin Oncol, 2021, 39(4): 328-337.
[8] CHEN JJ, QIAN PP, CAO K, et al.Comparison and Analysis of Causality Assessment Method in China and Naranjo's Method in the Evaluation of Adverse Drug Reactions[J]. Chinese Pharmaceutical Affairs(中国药事), 2020, 34(8): 988-992.
[9] CHEN S, WAN C, ZHANG YR.Research Progress of Cardiotoxicity Related to the Third Generation of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2024, 26(2): 106-110.
[10] CROSS DA, ASHTON SE, GHIORGHIU S, et al.AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer[J]. Cancer Discov, 2014, 4(9): 1046-1061.
[11] LU Z, WU CY, JIANG YP, et al. Suppression of Phosphoinositide 3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT Syndrome[J]. Sci Transl Med, 2012, 4(131): 131ra50.
[12] LI P, TIAN X, WANG G, et al.Acute Osimertinib Exposure Induces Electrocardiac Changes by Synchronously Inhibiting the Currents of Cardiac Ion Channels[J]. Front Pharmacol, 2023, 14: 1177003.
[13] HERRMANN J, YANG EH, ILIESCU C, et al.Response by Herrmann et al to Letter Regarding Article,“Vascular Toxicities of Cancer Therapies: the Old and the New-an Evolving Avenue”[J]. Circulation, 2016, 134(20): 466-467.
[14] Guidelines Working Committee of Chinese Society of Clinical Oncology. Cardio-Onclolgy Guideline 2023
(肿瘤心脏病学指南2023)[M]肿瘤心脏病学指南2023)[M]. Beijing: People's Medical Publishing House, 2023: 78.
[15] LYON AR, LOPEZ-FERNANDEZ T, COUCH LS, et al.2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)[J]. Eur Heart J, 2022, 43(41): 4229-4361.

甲磺酸伏美替尼片致心力衰竭1例分析

One Case of Heart Failure Caused by Furmonertinib Mesilate Tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	聂晓璐, 孙凤, 阎爱侠, 彭晓霞, 詹思延. 基于多源信息构建药品不良反应基准数据库[J]. 中国药物警戒, 2025, 22(1): 10-15.
[2]	聂晓璐, 赵厚宇, 霍东辉, 阎爱侠, 孙凤, 彭晓霞, 倪鑫, 詹思延. 基于真实世界数据与定量构效关系的儿童药源性免疫性血小板减少症研究[J]. 中国药物警戒, 2025, 22(1): 16-22.
[3]	邵波, 钟露苗, 成雨竹, 邓华, 朱兰. 银黄口服制剂安全性风险分析及思考[J]. 中国药物警戒, 2025, 22(1): 84-87.
[4]	赵秋月, 卫红涛, 李丹丹, 闫安, 邸宣. 阿加曲班注射液治疗急性缺血性脑卒中致消化道出血的不良反应分析[J]. 中国药物警戒, 2025, 22(1): 88-92.
[5]	戴彪, 曹银, 孙艳红, 张元元, 夏清荣. 808例抗精神病药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(1): 99-103.
[6]	程伟能, 潘秋娜, 杨静, 冯强, 汤晓萌, 梁悦. 763例药疹病例分析[J]. 中国药物警戒, 2025, 22(1): 104-108.
[7]	孟康康, 夏玉坤. 昂丹司琼制剂安全性风险分析[J]. 中国药物警戒, 2024, 21(9): 1034-1038.
[8]	吴凡, 付林杰, 祝赫, 徐梦艳. 基于美国FAERS和日本JADER数据库的内皮素受体拮抗剂不良事件信号分析[J]. 中国药物警戒, 2024, 21(9): 1056-1063.
[9]	卢靖, 喻珊珊, 童菲, 林卓慧, 宋路瑶. 达格列净片致严重便秘1例分析[J]. 中国药物警戒, 2024, 21(9): 1071-1074.
[10]	刘婷, 曹忠强, 何文佳, 袁秀丽, 陈泽彬, 李学娟. 培门冬酶注射液致急性重症胰腺炎1例分析[J]. 中国药物警戒, 2024, 21(9): 1075-1077.
[11]	魏芬芳, 吴文宇, 李丽敏, 唐碧雨, 吴建茹. 国外药品获益-风险评价方法概述与启示[J]. 中国药物警戒, 2024, 21(8): 900-905.
[12]	王玉玺, 张宗林, 王颖丽, 陈亚飞, 李俊生, 霍艳飞, 谢彦军, 刘文启. 560例脉络舒通丸不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 921-924.
[13]	赵俊, 董丽, 王洋, 梁瑜, 杨雪, 李恩泽. 艾司洛尔不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 925-930.
[14]	张乾, 恽渊, 何恋. 1例利培酮致高泌乳素血症患者的药学监护[J]. 中国药物警戒, 2024, 21(8): 936-938.
[15]	晁滢, 张学梅, 张成健, 王贝. 注射用头孢曲松钠致儿童输尿管结石及胆囊结石1例分析[J]. 中国药物警戒, 2024, 21(8): 943-945.